Compass Pathways Submits NDA for COMP360 Psilocybin for Treatment-Resistant Depression
Revolutionary Therapeutic Opportunity
Kabir Nath, CEO of Compass Pathways, stressed the need for this innovation. TRD sufferers have endured disproportionate suffering for too long. Conventional therapies have often failed to bring substantial relief. The NDA completion honors years of dedication. Patients, families, and researchers collaborated for this goal.
Leadership in Novel Medicine Development
Compass Pathways leads the development of this new drug class with rigor. The company completed a large late-stage clinical program for psychedelics. The entire Compass team deserves recognition for this milestone. They await the review process. The focus remains on rapid patient access post-approval. Compass already has a world-class commercial structure ready for wide patient access.
Efficacy Data from Phase 3 Trials
COMP360's effectiveness is supported by two Phase 3 studies: COMP005 and COMP006. Over 1000 participants were involved in these investigations. The results show a distinct profile for COMP360. This includes a fast onset of effect and remarkable response durability. The Phase 3 program specifically targeted chronically TRD patients.
COMP006 data showed participants with active depression lasting over three years. These patients had over six lifetime depressive episodes. In this severe group, 39% of those treated with 25 mg saw a significant MADRS score reduction ($\geq 25\%$) by week six. This was after two fixed doses of COMP360. Importantly, these patients maintained this stable response until week 26. This exceeds the 25% seen in the single-dose COMP005 study, highlighting the added benefit of a second dose.
Analysis of COMP006 Data
Gus Alva, an MD and investigator in both studies, noted transformative clinical responses. These responses require anchoring in psychological therapy and specialized therapist supervision. COMP360 may qualify for accelerated approval. The FDA granted a National Priority Voucher (NPV). This sets a review target of one to two months. Compass estimates a commercial launch in the first half of 2027 if approval is positive.
Clinical Oversight and Next Steps
This advance offers real hope to those with TRD. It is based on solid clinical evidence from rigorous study conditions. Companies and researchers continue working to bring this therapy to those who need it fastest.